<DOC>
	<DOCNO>NCT00575224</DOCNO>
	<brief_summary>The purpose research study test safety , tolerability , effectiveness drug Pegasys Copegus use hepatitis C genotypes 6 , 7 , 8 , 9 . Patients randomly assign ( chance ) either Treatment Group A ( Pegasys Copegus 24 week ) Treatment Group B ( Pegasys Copegus 48 week ) .</brief_summary>
	<brief_title>Pegasys Copegus Asian Patients With Treatment-naive Hepatitis C Genotypes 6 , 7 , 8 , 9</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>The subject must meet follow criterion entry . Subject must willing give write informed consent able adhere dose visit schedule . Adult subject 1870 year age gender race long HCV genotype 6 , 7 , 8 , 9 . Serum positive HCVRNA PCR ( qPCR ) assay , bDNA Liver biopsy within 24 month prior entry protocol pathology report confirm histological diagnosis consistent chronic hepatitis C stage II fibrosis . Biopsy must score reread score fibrosis stage grade severity steatosis . Compensated liver disease follow minimum hematologic , biochemical , serologic criterion Entry Visit ( WNL = within normal limit ) . Hemoglobin ( Hb ) great equal to12 gm/dL woman 13 gm/dL men . White blood cell count ( WBC ) great equal 2,000/mm3 Platelets ( PLT ) great equal 90,000/mm3 Direct bilirubin ( DB ) less equal 1.0 Indirect bilirubin ( IB ) = WNL great equal 3.0 mg/dL due nonhepatitis related factor Gilbert 's disease . Creatinine ( Cr ) clearance great equal to50 mL/minute serum Cr great equal 1.5x UNL screening . Fasting glucose ( FBS ) less equal to160 mg/dL Hb A1c great equal 8.5 % diabetic subject ( whether medication diet control ) . Thyroid Stimulating Hormone ( TSH ) = WNL ( Subjects require medication maintain TSH level normal range eligible inclusion/exclusion criterion meet . ) Serum antiHIV = negative Serum HBsAg = negative Abdominal ultrasound negative liver mass within 3 month prior entry . Patients without cirrhosis transition cirrhosis may image study do within 12 month study entry . Alphafetoprotein ( AFP ) less equal 20 ng/mL obtain within 3 month prior entry . Patients 20 ng/mL less equal AFP le equal 100ng/mL may enrol normal biphasic abdominal CT within previous 3 month patient Stage III/IV fibrosis normal ultrasound patient Stage I/II fibrosis . If AFP 100 less 200 ng/dL , patient need negative biphasic CT within 3 month . Female subject must breastfeed . A pregnancy test must obtain within 24 hour first dose study drug must negative . Additionally , fertile male female must use two reliable form effective contraception ( combine ) treatment study drug 6 month treatment completion . Acceptable form contraception may include intrauterine device , oral contraceptive , progesterone implant rod [ Norplant ] , medroxyprogesterone acetate [ DepoProvera ] , surgical sterilization , barrier method [ diaphragm + spermicide condom + spermicide ] The subject exclude entry follow criterion apply : Women pregnant breast feeding . Male partner woman pregnant . Suspected hypersensitivity interferon , PEGinterferon Copegus . Treatment investigational drug within 45 day entry protocol . Therapy systemic antiviral , antineoplastic immunomodulatory treatment great equal to6 month prior first dose study drug , except PEGIFN alfa2b ribavirin . This include amantadine , mycophenolate mofetil , thymosine alpha , viramidine , levovirin , supraphysiologic dos steroid ( great equal 10 mg/d great equal 14 consecutive day prednisone equivalence ) radiation , exception : patient limit ( great equal 7 day ) course acyclovir valacyclovir herpetic lesion 1 month prior first administration test drug exclude . Any cause liver disease chronic hepatitis C include limited : Coinfection HBV Hemochromatosis ( iron deposition great equal to2+ severe liver parenchyma ) Alpha1 antitrypsin deficiency Wilson 's disease Autoimmune hepatitis Alcoholic liver disease Significant obesityinduced liver disease ( elevated ALT BMI great equal 30 ) Drugrelated liver disease Hemophilia condition would prevent subject liver biopsy , include anticoagulant therapy . Hemoglobinopathies ( e.g. , Thalassemia ) significant anemia . History evidence decompensated liver disease ChildPugh score 6 . Coagulopathy , hyperbilirubinemia , hepatic encephalopathy , hypoalbuminemia , ascites , bleed esophageal varix condition consistent decompensated liver disease . Patients history hepatocellular carcinoma . Any known preexisting medical condition could interfere subject 's participation completion protocol : A history preexist psychiatric condition , especially severe depression , history severe psychiatric disorder , major psychosis , suicidal ideation and/or suicidal attempt exclude . Severe depression would include follow : ( ) subject hospitalized depression , ( b ) subject receive electroconvulsive therapy depression , ( c ) subject whose depression result prolonged absence work and/or significant disruption daily function . Subjects history mild depression may consider entry protocol provide pretreatment assessment subject 's mental status support subject clinically stable . The Investigator formulate management plan subject become part subject 's medical record . The management plan may develop conjunction health care professional trained psychology . For subject , Investigator review subject 's mental status every visit . CNS trauma active seizure disorder require medication . Significant cardiovascular dysfunction within past 12 month ( e.g. , angina , congestive heart failure , recent myocardial infarction , severe uncontrolled hypertension significant arrhythmia ) . Subjects ECG show clinically significant abnormality . Poorly control diabetes mellitus . Chronic pulmonary disease ( e.g. , chronic obstructive pulmonary disease ) , document pulmonary hypertension . Immunologically mediated disease ( e.g. , inflammatory bowel disease [ Crohn 's disease , ulcerative colitis ] , rheumatoid arthritis , idiopathic thrombocytopenia purpura , systemic lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis , clinical cryoglobulinemia vasculitis ) . Clinical gout . Any patient increase baseline risk anemia ( e.g . thalassemia thalassemia trait , spherocytosis , history GI bleeding , etc ) anemia would medically problematic Patients , judgment investigator , acute decrease hemoglobin 4 g/dL ( 40 g/L ) ( may see ribavirin therapy ) would welltolerated . History immunologically mediate disease ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis , rheumatoid arthritis etc . ) History major organ transplantation exist functional graft Substance abuse , alcohol ( great equal 80 gm/day ) , IV drug inhale drug . If subject history substance abuse , consider inclusion protocol , subject must abstain use abused substance least 12 month . Stable subject enrol methadone maintenance program least one year may enrol otherwise eligible monitor throughout study illicit drug use . Subjects willing abstain consumption alcohol . Subjects severe retinopathy ( e.g . CMV retinitis , macular degeneration ) clinically significant retinal abnormality . Inability unwillingness provide inform consent abide requirement study . Any condition , opinion Investigators would make subject unsuitable enrollment , could interfere subject participate complete protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Genotype 6</keyword>
	<keyword>Novel genoytpe</keyword>
	<keyword>HCV</keyword>
	<keyword>Treatment</keyword>
</DOC>